Clinical significance of extended-spectrum β-lactamases

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 5, 2008, Pages 671-683

  Rodríguez Baño, Jesús ^a   Pascual, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Antimicrobial therapy; Escherichia coli; Extended spectrum lactamase; Klebsiella pneumoniae; Mortality; Risk factor; lactamase

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TIGECYCLINE; UNINDEXED DRUG;

BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNICABLE DISEASE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; ENTEROBACTER; ENTEROBACTER INFECTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SYNTHESIS; EPIDEMIC; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PERITONITIS; POPULATION RESEARCH; PREVALENCE; PROTEIN FAMILY; PROTEUS; PYELONEPHRITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALMONELLA; SEPTIC SHOCK; SERRATIA; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 55249126864     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.5.671     Document Type: Review

References (125)

1. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4), S131-S138 (2006).
2. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Med. 119(6 Suppl. 1), S20-S22 (2006).
3. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Soceity of Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44(2), 159-177 (2007).
4. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
5. Cantón R, Coque TM. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol. 9(5), 466-475 (2006).
6. Lewis JS II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 51(11), 4015-4021 (2007).
7. Livermore DM, Cantón R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59(2), 165-175(2007).
8. Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin. Microbiol. Infect. 14(Suppl. 1), 42-52 (2008).
9. Rodríguez-Baño J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin. Infect. Dis. 42(7), 935-937 (2006).
10. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med. 136(11), 834-844 (2002).
11. Rogues AM, Boulard G, Allery A et al. Thermometers as a vehicle for transmission of extended-spectrum β-lactamase-producing Klebsiella pneumoniae. J. Hosp. Infect. 45(1), 76-77 (2000).
12. Macrea MB, Shannon KP, Rayner DM, Kaiser AM, Hoffman PN, French GL. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J. Hosp. Infect. 49(3), 183-192 (2001).
13. Harris AD, Perencevich EN, Johnson JK et al. Patient-to-patient transmission is important in extended-spectrum β-lactamase-producing Klebsiella pneumoniae acquisition. Clin. Infect. Dis. 45(10), 1347-1350 (2007).
14. Valverde A, Coque MT, Sánchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situation in Spain. J. Clin. Microbiol. 42(10), 4769-4775 (2004).
15. Miró E, Mirelis B, Navarro F et al. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J. Antimicrob. Chemother. 56(6), 1152-1155 (2005).
16. Castillo García FJ, Seral García C, Pardos de la Gándara M et al. Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods. Eur. J. Clin. Microbiol. Infect. Dis. 26(1), 77-78 (2007).
17. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Inject. Control Hosp. Epidemiol. 28(9), 1114-1116 (2007).
18. Pallecchi L, Bartoloni A, Fiorelli C et al. Rapid dissemination and diversity of CTX-M extended-spectrum β-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob. Agents Chemother. 51(8), 2720-2725 (2007).
19. Rodríguez-Baño J, López-Cerero L, Navarro MD, Diaz de Alba P, Pascual A. Faccal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J. Antimicrob. Chemother. PMID: 18641033 (2008) (Epub ahead of print).
20. Mesa RJ, Blanc V Blanch AR et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J. Antimicrob. Chemother. 58(1), 211-215 (2006).
21. Doi Y, Paterson DL, O'Keefe A et al. Cephalosporin-resistant Escherichia coli from retail meat in Spain and the United States. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA 17-20 (2007).
22. Warren RE, Ensor VM, O'Neill P et al. Imported chicken as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum β-lactamases in the UK. J. Antimicrob. Chemother. 61(3), 504-508 (2008).
23. Romero L, López L, Rodríguez-Baño J et al. Long term study of the frequency of extended-spectrum β-lactamases-producing Escherichia coli and Klebsiella pneumoniae isolates. Clin. Microbiol. Infect. 11(8), 625-631 (2005).
24. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56(1), 52-59 (2005).
25. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Agents 61(2), 273-281 (2008).
26. Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A; the Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob. Agents Chemother. 49(5), 2122-2125 (2005).
27. Rodríguez-Baño J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin. Infect. Dis. 42(1), 37-45 (2006).
28. Peña C, Gudiol C, Tubau F et al. Risk-factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalized patients. Clin. Microbiol. Infect. 12(3), 279-284 (2006).
29. Cantón R, Oliver A, Coque TM, Varela MC, Pérez-Díaz JC, Baquero F. Epidemiology of extended-spectrum β-lactamase-producing isolates in a Spanish hospital during a 12-year period. J. Clin. Microbiol. 40(4), 1237-1243 (2002).
30. Valverde A, Coque MT García San Miguel L, Baquero F, Cantón R. Complex molecular epidemiology of extended-spectrum β-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. J. Antimicrob. Chemother. 61(1), 64-72 (2008).
31. Garcia D de O, Doi Y, Szabo D et al. Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum β-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. Antimicrob. Agents Chemother. 52(5), 1790-1793 (2008).
32. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin. Infect. Dis 42(7), 925-934 (2006).
33. Harris AD, Kotetishvilli M, Shurland S et al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am. J. Infect. Control 35(2), 97-191 (2007).
34. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis. 61(2), 203-213 (2008).
35. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn. Microbiol. Infect. Dis. 60(2), 185-192 (2008).
36. Hirakata Y, Matsuda J, Miyazaki Y et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn. Microbiol. Infect. Dis. 52(4), 323-329 (2005).
37. Rossi F, Baquero F, Hsueh PR et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58(1), 205-120 (2006).
38. Behar PRP, Texeira PJZ, Fachel JMG, Falid AC. The effect of control group selection in the analysis of risk factors for extended-spectrum β-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J. Hosp. Infect. 68 (2), 123-129 (2008).
39. Harris AD, Karchmer TB, Carmeli Y, Samore SH. Methodological principles of case-control studies that analysed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32(7), 1055-1061 (2001).
40. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am. J. Infect. Control 35 (9), 606-612 (2007).
41. Rodríguez Baño J, Navarro MD, Romero L et al. Risk factors for emerging bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin. Microbiol. Infect. 14(2), 180-183 (2008).
42. Ling MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J. Hosp. Infect. 53(1), 39-45 (2003).
43. Paterson DL, Ko WC, Von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med. 140(1), 26-32 (2004).
44. Lee SO, Lee ES, Park SY, Kim SY, Seo Y, Cho YK. Reduced use of third generation cephalosporins decreased the acquisition of extended-spectrum β-lactamase producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25(10), 832-837 (2004).
45. Kang CI, Ki SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25(10), 860-867 (2004).
46. Silva N, Oliveira M, Bandeira AC, Brites C. Risk factors for infection by extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a tertiary hospital in Salvador, Brazil. Braz. J. Infect. Dis. 10(3), 191-193 (2006).
47. Peña C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended-spectrum β-lactamase (ESBL-KP) in the intensive care unit. J. Hosp. Infect. 35(1), 9-16 (1997).
48. Rebuck JA, Olsen KM, Fey PD, Langas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin. Infect. Dis. 31(6), 1368-1372 (2000).
49. Asensio A, Oliver A, González-Diego P et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin. Infict. Dis. 30(1), 55-60 (2000).
50. Gupta A, Della-Latta P, Todd B et al. Outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails. Infect. Control Hosp. Epidemiol. 25(3), 210-215 (2004).
51. Boo NY, Ng SG, Lim VK. A case-control study of risk factors associated with rectal colonization of extended-spectrum β-lactamase-producing Klebsiella spp. in newborn infants. J. Hosp. Infect. 61(1), 68-74 (2005).
52. Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection in children; a case-control retrospective study in a medical center in southern Taiwan. J. Clin. Immunol. Infect. 40(3), 248-254 (2007).
53. Kristóf K, Szabó D, Marsh JW et al. Extended-spectrum β-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology. Eur. J. Clin. Microbiol, Infect. Dis. 26 (8), 563-570 (2007).
54. CTX-M genes. Clin. Infect. Dis. 38(12), 1736-1741 (2004).
55. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J. Clin. Microbiol. 42(3), 1089-1094 (2004).
56. Calbo E, Romaní V, Xercavins M et al. Risk factors for comrnunity-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J. Antimicrob. Chemother. 57(4), 780-183 (2006).
57. Colodner R, Rock W, Chazan B, Keller N, Guy N, Raz R. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in non-hospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23(3), 163-167 (2004).
58. Ena J, Arjona F, Martínez-Peinado C, López-Perazagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Urology 68(6), 11169-11174 (2006).
59. Moor CT, Roberts SA, Simmons G et al. Extended-spectrum β-lactamase (ESBL)-producing enterobacteria; factors associated with infection in the community setting, Auckland, New Zealand. J. Hosp. Infect. 68(4), 355-362 (2008).
60. Rodriguez-Baño J, Alcalá JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase producing- Escherichia coli. Arch. Intern. Med. (2008) (In press).
61. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum lactamase: a case-control study of risk factors and outcomes. Scand. J. Infect. Dis. 34(8), 567-573 (2002).
62. Peña C, Pujol M, Ardanuy C et al. An outbreak of hospital acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase. J. Hosp. Infect. 47(1), 53-59 (2001).
63. Peña C, Pujol M, Ardanuy C et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 42(1), 53-58 (1998).
64. Hyle EP, Lipwoth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Arch. Intern. Med. 165(12), 1375-1380 (2005).
65. Garcia San Miguel L, Cobo J, Valverde A et al. Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum β-lactamases. Clin. Microbiol. Infect. 13(5), 532-538 (2007).
66. Richards C, Alonso-Echanove J, Caicedo Y, Jarvis WR. Klebsiella pneumoniae bloodstream infections among neonates in a high-risk nursery in Cali, Colombia. Infect. Control Hosp. Epidemiol. 25(3), 221-225 (2004).
67. Reddy P, Malcynski M, Obias A et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin. Infect. Dis. 45(7), 846-852 (2007).
68. Rodríguez-Baño J, García L, Durán L et al. Control of an extensive and prolonged outbreak caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal unit. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 27-30 September (2006).
69. Kim JBN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect. 52(2), 99-106 (2002).
70. Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect. Dis. 6, 24 (2006).
71. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50(2), 498-504 (2006).
72. McMullan R, Loughrey AC, McCalmont M, Rooney PJ. Clinico-epidemiological features of infections caused by CTX-M type extended-spectrum β-lactamase-producing Escherichia coli in hospitalised patients. J. Infect. 54(1), 46-52 (2007).
73. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L; Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de β-lactamasas de espectro extendido en hospitales españoles (proyecto GEIH-BLEE 2000). Enferm. Infecc. Microbiol. Clin. 21(2), 77-82 (2003).
74. Metan G, Zarakolu P, Cakir B, Hascelik G, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Int. J. Antimicrob. Agents 26(3), 254-257 (2005).
75. Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43(11), 1407-1414 (2006).
76. Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M type extended-spectrum β-lactamase-producing Escherichia coli. Diag. Microbiol. Infect. Dis. 56(4), 351-357 (2006).
77. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 27(1), 85-88 (2008).
78. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended-spectrum β-lactamase (ESBL) producing E. coli compared with non-ESBL producing E. coli. J. Infect. 55(3), 254-259 (2007).
79. Hammami A, Arlet G, Ben Redjeb S et al. Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in Tunisia caused by multiply drug resistant Salmonella wien producing SHV-2 β-lactamase. Eur. J. Clin. Microbiol. Infect. Dis. 10(8), 641-646 (1991).
80. Morisini MI, Blázquez J, Negri MC, Cantón R, Loza E, Baquero F. Characterization of a nosocomial outbreak involving an epidemic strain encoding for TEM-27 in Salmonella enterica serotype Othmarchen. J. Infect. Dis. 174(5), 1015-1020 (1996).
81. Bouallegue-Godet O, Ben Salem Y, Fabre L et al. Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum β-lactamase in a neonatal unit in Sousse, Tunisia. J. Clin. Microbiol. 43(3), 1037-1044 (2005).
82. Yong D, Lim YS, Yum JH et al. Nosocomial outbreal of pediatric gastroenteritis caused by CTX-M-14-type extended-spectrum β-lactamase-producing Salmonella enterica serovar London. J. Clin. Microbiol. 43(7), 3519-3521 (2005).
83. Wadula J, Von Gotteberg A, Kilner D et al. Nosocomial outbreak of extended-spectrum β-lactamase-producing Salmonella isangi in pediatric wards. Pediatr. Infect. Dis. J. 25(9), 843-844 (2006).
84. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 49(7), 2598-2605 (2005).
85. Manzur A, Tubau F, Pujol M et al. Nosocomial outbreak due to extended-spectrum β-lactamase-producing Enterobacter cloacae in a cardiothoracic intensive care unit. J. Clin. Microbiol. 45(8), 2364-2369 (2007).
86. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60(5), 913-920 (2007).
87. Marcos M, Soriano A, Martínez JA, Mensa J. Septic shock should be included in multivariable analysis models analysing the effect of empirical antibiotic therapy of mortality. Clin. Infect. Dis. 45(10), 1410 (2007).
88. Lavigne JP, Blanc-Potard AB, Bourg G et al. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M β-lactamases. Clin. Microbiol. Infect. 12(12), 1199-1206 (2006).
89. Karisik E, Ellington MJ, Livermore DM, Woodford N. Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum β-lactamases in UK. J. Antimicrob. Chemother. 61, 54-50 (2008).
90. Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Agents 61, 1024-1028 (2008).
91. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz C, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50(4), 1257-1262 (2006).
92. Peña C, Gudiol C, Calatayud L et al. Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality. J. Hosp. Infect. 68 (2), 116-122 (2008).
93. Anderson DJ, Engemann JJ, Harrel LJ, Carmeli Y, Barth Reller L, Kaye KS. Predictors of mortality in patients with bloodstream infections due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 50(5), 1715-1720 (2006).
94. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51(6), 1987-1994 (2007).
95. Peralta G, Sánchez MB, Garrido JC et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteremia. J. Antimicrob. Chemother. 60(4), 855-863 (2007).
96. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39(6), 2206-2212 (2001).
97. Wong-Beringer A, Hindler J, Loeloff M et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 34(2), 135-146 (2002).
98. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis. 39(1), 31-37 (2004).
99. Endimiani A, Luzzaro F, Perilli M et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38(2), 243-251 (2004).
100. Frei CR, Wiederhold N, Burgess DS. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodymanic models with Monte Carlo simulations. J. Antimicrob. Chemother. 61(3), 621-628 (2008).
101. Clinical and Laboratory Standards Institute. Methods For Dilution Antimicrobial Susceptibility Test For Bacteria That Grow Aerobically (7th Edition). Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2006).
102. Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int. J. Antimicrob. Agents 28(5), 457-459 (2006).
103. Bassetti M, Righi E, Fasce R et al. Efficacy of ertapenem in the treatment if early ventilator-associated pneumonia caused extended-spectrum β-lactamase-producing organisms in an intensive care unit. J. Antimicrob. Chemother. 60(2), 433-435 (2007).
104. Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treament of extended-spectrum β-lactamase-producing Gram-negative bacterial infections. Int. J. Antimicrob. Agents 30(4), 356-359 (2007).
105. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing Gram-negative infections: a case series report. Ann. Pharmacother. 42(2), 207-212 (2008).
106. Szabo D, Silveira F, Hujer AM et al. Outer membrane protein changes and efflux pump expression together may confer resistence to ertapenem in Enterobacter cloacae. Antimicrob. Agents Chemother. 50(8), 2833-2835 (2006).
107. Elliot E, Brink AJ, Van Greune J et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase. Clin. Infect. Dis. 42(11), E95-E98 (2006).
108. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin. Microbiol. Infect. 11 (Suppl. 6), 10-17 (2005).
109. MacGowan A. Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriaceae: pharmacokinetic/pharmacodynamic considerations. Clin. Microbiol. Infect. 14(Suppl. 1), 166-168 (2008).
110. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the United Kingdom. J. Antimicrob. Chemother. 58(3), 665-668 (2006).
111. Doménech-Sánchez A, Pascual A, Suárez AI, Alvarez D, Benedí VJ, Martínez-Martínez L. Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum β-lactamases and deficient or not in porins. J. Antimicrob. Chemother. 46(5), 858-859 (2000).
112. Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diag. Microbiol. Infect. Dis. 57(3), 341-344 (2007).
113. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-taxobactam against Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47(5), 1643-1646 (2003).
114. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56(3), 451-454 (2005).
115. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6(9), 589-601 (2006).
116. Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev. Anti Infect. Ther. 4(4), 601-618 (2006).
117. Morosini MI, Garcia-Castillo M, Coque TM et al. Antibiotic coresistance in extended-spectrum β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50(8), 2695-2699 (2006).
118. Livermore DM. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56(4), 611-614 (2005).
119. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J. Clin. Microbiol. 46(5), 1892-1893 (2008).
120. Krueger WA, Kempf VA, Peiffer M, Nagele U, Unertl KE, Schroeder TH. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase-producing Escherichia coli. J. Clin. Microbiol. 46 (2), 817-820 (2008).
121. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 59(1), 128-131 (2007).
122. Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60(3), 319-322 (2008).
123. de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de β-lactamasas de espectro extendido. Enferm. Infecc. Microbiol. Clin. 24(10), 613-616 (2006).
124. Pullucku H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related urinary tract infections. Int. J. Antimicrob. Agents 29(1), 62-65 (2007).
125. Garau J. Other antimicrobials of interest in the era of extended-spectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microb. Infect. 14(Suppl. 1), 198-202 (2008).